Condition: Prostate Cancer Patients on Active Surveillance · Sponsor: Ashutosh Kumar Tewari
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
This description comes directly from the study's public registry record.
Monali Fatterpekar, PhD · 212-241-0751 · monali.fatterpekar@mountsinai.org
Cristina Pasat-karasik, RN · Cristina.Pasat-karasik@mountsinai.org
Always discuss trial participation with your own doctor first.
| Icahn School of Medicine at Mount Sinai (ISMMS) | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06343077